Can a new pill outsmart RAS-Mutant cancers?

NCT ID NCT07746141

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental oral drug called BG-85738 in people with advanced or metastatic solid tumors that have RAS mutations. The study aims to see if the drug is safe and tolerable when given alone or combined with other anti-cancer agents, and to get an early read on whether it can shrink tumors. About 100 adults with these hard-to-treat cancers are being enrolled to help determine the right dose and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BG-85738, an experimental oral drug, tested alone or with tislelizumab or cetuximab
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have RAS mutations, potentially slowing or shrinking their cancer.
What could go wrong
This is an early-phase trial, so the drug may not be safe or effective. Side effects are possible, and the results may not apply to all patients with RAS-mutant tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.